A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma

Trial Profile

A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Varlilumab (Primary) ; CDX 1401; Poly ICLC
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 06 Mar 2017 Status changed from completed to discontinued due to Feasibility concerns due to changes in standard of care.
    • 23 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2016 Planned End Date changed from 1 Dec 2020 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top